7 results
The objective of this study is to assess the distribution of infusion associated reactions (IARs) by severity grade when Lemtrada is administered to RRMS patients who will be medicated according to specified algorithm designed to manage infusion…
To evaluate the long-term safety and efficacy of alemtuzumab, for patients already treated with this medicine in preceding clinical trials (CARE-MS I, CARE-MS II and CAMMS03409).
The primary objective is to examine whether a combined treatment with rivastigmine (cholinesterase inhibitor) and citalopram (selective serotonin re-uptake inhibitor) will improve memory as compared to the treatment with either rivastigmine or…
• To perform full kinetic modeling of [18F]F-AraG for the uptake in tumor lesions and healthy organs (e.g. spleen) by exploring different kinetic models and outcome measures as well as its test-retest (TRT) variability to guide the selection of an…
Primary objective:To evaluate the efficacy, safety and tolerability of alemtuzumab intravenously (IV) in paediatric patients from 10 to <18 years of age with relapsing remitting multiple sclerosis (RRMS) who have disease activity on prior…
• To assess the relative change in uptake of [18F]F-AraG in tumor lesions upon anti-PD-1 treatment• To assess the relationships between baseline tumor [18F]F-AraG uptake, change of tumor [18F]F-AraG uptake and tumor response to anti-PD-1 therapy
The objective of this prospective, randomized study is to investigate the efficacy and safety of HSCT compared to the comparator group (alemtuzumab, cladribine or ocrelizumab) in patients with aggressive relapsing remitting MS. In Norway, the…